ClinicalTrials.gg
RecruitingNCT05917626Digital SPAUpdated Dec 15, 2025

Effectiveness and Implementation of a Digital Intervention for Pediatric Chronic Pain Co-designed With Patients

An interventional study of Digital SPA in Chronic Pain, sponsored by University of Malaga. Recruiting at 6 sites in Spain. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by University of Malaga · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
195
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Chronic Pain by University of Malaga — 2 open to participants now, 2 under way, none of them phase 3. Chronic Pain · University of Malaga.

Started
2023
the only one that year
No phase
9 of 12
2 open now
Registered
11th of 12
by date

Among the 12 studies in Chronic Pain by University of Malaga, this one is the only one that started in 2023, is one of 9 with no phase, and was the 11th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

2 of the 12 studies in Chronic Pain by University of Malaga are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Chronic Pain by University of Malaga, or all of them as a file.
02

Study summary

Children and adolescents with chronic pain often lack a proper diagnosis and treatment. Research has shown that, if left untreated, it usually doesn't resolve and continues through adulthood.

The goal of this multi-phase study is to co-develop (with patients), test, and implement a smartphone app called "Digital Solution for Pain in Adolescents" (Digital SPA) which can provide pain management resources to children with chronic pain and their parents, preventing future disability.

Participants will: participate in individual and group interviews, respond to questionnaires online and try a smartphone app.

Read the detailed description

Phase 1) Focus groups with patients, parents and clinicians (n = 5-6 each) will inform about unmet pain care needs, and provide a starting point for co-designing the intervention.

Phase 2) Content creation and usability testing will be based on the results of Phase 1 and the theory-driven development will follow the latest available evidence and the World Health Organization guidelines on the management of chronic pain in children. The intervention will use validated psychological techniques (particularly Cognitive Behavioral Therapy and Acceptance and Commitment Therapy) focused on improving functioning by teaching pain coping skills, such as: relaxation, goal setting, sleep management, behavioral activation, self-management of negative thoughts and emotions, and communication skills.

Phase 3) Effectiveness and Implementation study. Participants (n = 195) will be adolescents 12-17 years old with chronic pain admitted into any of 6 large hospitals in Spain and one of their parents.

03

Conditions studied

  • Chronic Pain

Browse trials for

Keywords

  • Chronic pain
  • Adolescents
  • Digital Health
  • Psychological Intervention
  • Co-development
  • Implementation
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescents age 12-17 years
  • Has had non-oncologic chronic pain for at least 3 months (e.g., abdominal pain, headache or musculoskeletal pain)
  • Has Internet access
  • One parent is willing to participate (and both give consent for their child to participate)

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of a comorbid serious health condition (e.g., cancer)
  • Parent or child does not speak or read Spanish
  • Active psychosis or suicidal ideation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
195 participants (estimated)

Study arms

  • Experimental
    Digital SPA

    A psychological intervention for chronic pain in adolescents administered using an app co-created with patients.

    Behavioral: Digital SPA

  • No intervention
    Usual Care

    Participants assigned to this arm will receive usual care from their hospital.

Interventions

  • BehavioralDigital SPA

    A psychological digital intervention for chronic pain in adolescents, based on evidence-based Acceptance and Commitment Therapy techniques. The intervention will be co-created with patients in a previous phase of the study, so the exact number or format of sessions and content has not been determined yet.

06

What researchers measure

Primary outcomes

  1. Change in Pain Interference

    Spanish version of the Brief Pain Inventory (BPI) short version. Pain intensity scale scores range from from 0 to 10 , with higher scores indicating greater interference. Interference scores range from 0 to 10, with higher scores indicating greater interference.

    Time frame: Pre-treatment (T1), Mid-treatment (T2; 4 weeks after T1), Post-treatment (T3; 8 weeks after T1) and 3-months follow-up (T4; 3 months after T3).

  2. Global impression of change after treatment

    11-point scale (0 to 10) with higher scores indicating greater impression of change.

    Time frame: Post-treatment (T3; 8 weeks after T1) and 3-months follow-up (T4; 3 months after T3).

  3. Change in the number of visits to the Emergency Room (ER) due to pain

    The number of visits to the ER due to pain during the follow-up period (T3 to T4; 3 months) will be compared with the three months before starting treatment (T1).

    Time frame: Pre-treatment (T1), Mid-treatment (T2; 4 weeks after T1), Post-treatment (T3; 8 weeks after T1) and 3-months follow-up (T4; 3 months after T3).

Secondary outcomes

  1. Change in pain readiness to change

    Readiness to adopt a self-management approach to pain. The Spanish version of the Pain Stages of Change Questionnaire for Adolescents (PSoCQ-A). The Questionnaire has three scales: Pre-contemplation, Contemplation, and Action/Maintenance. Each scale is scored in a 1 to 5 Likert scale, with higher scores indicating a higher level of attitudes in that stage of change. The scale with the highest score indicates which stage the respondent is at.

    Time frame: Pre-treatment (T1), Mid-treatment (T2; 4 weeks after T1), Post-treatment (T3; 8 weeks after T1) and 3-months follow-up (T4; 3 months after T3).

  2. Change in the dose of pain medication taken

    The dose (eg. 25 mg per day) of pain medication taken will be recorded.

    Time frame: Pre-treatment (T1), Mid-treatment (T2; 4 weeks after T1), Post-treatment (T3; 8 weeks after T1) and 3-months follow-up (T4; 3 months after T3).

  3. Change in the type of pain medication taken

    The type (e.g. Non-steroid Anti-inflammatory Drugs, opioids) of pain medication taken will be recorded.

    Time frame: Pre-treatment (T1), Mid-treatment (T2; 4 weeks after T1), Post-treatment (T3; 8 weeks after T1) and 3-months follow-up (T4; 3 months after T3).

  4. Change in Emotional Distress

    The Spanish version of the Social Emotional Distress Scale-Secondary (SEDS-S) will be administered to assess general emotional distress (internalizing symptoms such as anxiety and depression) over the past month. The SEDS-S is a 10-item self-report questionnaire; items are rated from 1 ("Not at all true") to 4 ("Very true / Absolutely true"), with higher total scores indicating greater emotional distress.

    Time frame: Pre-treatment (T1), Mid-treatment (T2; 4 weeks after T1), Post-treatment (T3; 8 weeks after T1) and 3-months follow-up (T4; 3 months after T3).

  5. Change in Functional Disability

    Spanish version of CALI-9. Disability in functioning due to pain (activity limitations) is measured through 9 items to evaluate pain-related activity limitations in youth with chronic pain. Scores range from 1 = not very difficult; to 5 = extremely difficult. Higher scores indicating greater interference with children's activities.

    Time frame: Pre-treatment (T1), Mid-treatment (T2; 4 weeks after T1), Post-treatment (T3; 8 weeks after T1) and 3-months follow-up (T4; 3 months after T3).

  6. Change in Sleep

    Sleep quality will be assessed with the Spanish version of the Pittsburgh Sleep Quality Index, validated for adolescents (PSQI). Scores on 7 components range from 0 to 3, and are the summed (global score range 0 to 21, with higher scores indicating worse sleep quality). Insomnia will be assessed with the Spanish version of the Adolescent Insomnia Questionnaire (AIQ). Total scores range from 0 to 52 with higher scores indicating more insomnia symptoms.

    Time frame: Pre-treatment (T1), Mid-treatment (T2; 4 weeks after T1), Post-treatment (T3; 8 weeks after T1) and 3-months follow-up (T4; 3 months after T3).

  7. Change in Pain Self-efficacy

    Pain self-efficacy will be assessed using the Pain Self-Efficacy Questionnaire (PSEQ). The PSEQ is a 10-item self-report measure that evaluates the extent to which individuals feel capable of functioning despite their pain. Items are rated on a 7-point scale from 0 ("not at all confident") to 6 ("completely confident"). Total scores range from 0 to 60, with higher scores indicating greater pain-related self-efficacy.

    Time frame: Post-treatment (T3; 8 weeks after T1) and 3-months follow-up (T4; 3 months after T3).

  8. Psychological Flexibility and Inflexibility Processes

    Psychological flexibility and inflexibility will be assessed using the Multidimensional Psychological Flexibility Inventory (MPFI). The MPFI includes subscales capturing both flexibility and inflexibility across six ACT processes. Items are rated on a 1 ("never true") to 6 ("always true") scale. Subscale scores are computed by summing item responses, with higher scores indicating greater levels of the corresponding process (higher flexibility or higher inflexibility). A global index of psychological flexibility will also be measured using the PsyFlex questionnaire. The PsyFlex consists of 6 items rated on a 1 ("very untrue of me") to 5 ("very true of me") scale. Total scores range from 6 to 30, with higher scores indicating greater psychological flexibility.

    Time frame: Pre-treatment (T1), Mid-treatment (T2; 4 weeks after T1), Post-treatment (T3; 8 weeks after T1) and 3-months follow-up (T4; 3 months after T3).

  9. Satisfaction with treatment

    Usability and satisfaction with the intervention will be assessed using the mHealth App Usability Questionnaire (MAUQ). The MAUQ includes 18 items rated on a 1 ("strongly disagree") to 7 ("strongly agree") scale. Subscales assess ease of use, interface and satisfaction, and usefulness. Higher scores indicate greater usability and satisfaction with the digital intervention.

    Time frame: Post-treatment (T3; 8 weeks after T1).

  10. Adherence to treatment

    One measure of implementation will be adherence to the online intervention assessed collecting back-end data such as: number of log-ins or number of treatment sections completed.

    Time frame: From the moment the treatment app is downloaded (T1), to the completion of the treatment period (T3). Up to 10 weeks.

Other outcomes

  1. Adverse Events (side effects)

    Adverse Events are not expected given the content of the treatment and its non-invasive nature, however, they will be assessed, recorded and controlled for in the analyses

    Time frame: Mid-treatment (T2; 4 weeks after T1), Post-treatment (T3; 8 weeks after T1) and 3-months follow-up (T4; 3 months after T3).

07

Study locations

6 of 6 sites recruiting
08

References and documents

Publications

  • de la Vega R, Serrano-Ibanez ER, Ruiz-Parraga GT, Palermo TM, Wicksell R, Fernandez-Jimenez E, Oliva S, Roldan S, Monfort L, Pelaez MJ, Leyva Carmona M, Ramirez-Maestre C, Lopez-Martinez AE, Miro J, Esteve R. Protocol for a multi-phase, multi-center, real-world, hybrid effectiveness-implementation study of a digital intervention for pediatric chronic pain co-designed with patients (Digital SPA). Digit Health. 2023 Dec 19;9:20552076231219490. doi: 10.1177/20552076231219490. eCollection 2023 Jan-Dec. PubMed 38130799 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Oct 2027, 53 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 53 months is above that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2023
First posted
Jun 26, 2023
StartActual
May 5, 2023
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05917626
Collaborators
Ministerio de Ciencia e Innovación, Spain
Responsible party
Rocio de la Vega de Carranza, PhD ("Ramón y Cajal" Researcher; Principal Investigator, University of Malaga) — Principal investigator
First posted
Jun 26, 2023
Start date
May 5, 2023
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Dec 15, 2025

Study contacts

Rocio de la Vega, PhD
Contact
rocio.delavega@uma.es
+34634014362
Rocio de la Vega, PhD
principal investigator · University of Malaga

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion